Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 9-16

  Miceli, Marisa H ^a   Chandrasekar, Pranatharthi ^b  

^a OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efficacy and safety; Empiric therapy; Immunocompromised hosts; Invasive fungal infections; Polyenes

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; VORICONAZOLE;

ABNORMAL VISION; ADVERSE OUTCOME; ANEMIA; ANTIFUNGAL ACTIVITY; CANDIDIASIS; CHILL; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPOKALEMIA; HYPOXIA; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; INFUSION RELATED REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; MUCORMYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; SYSTEMIC MYCOSIS; THROMBOPHLEBITIS; TREATMENT INDICATION;

EID: 84861369293     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy. 2008;28(5):614-645.
2. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11:142-151.
3. Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54(6):e666-e678.
4. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol. 2008;46(3):933-938.
5. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. 2003;123(5 Suppl):500S-503S.
6. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2005. An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45(6):1735-1745.
7. Baddley JW, Moser SA. Emerging fungal resistance. Clin Lab Med. 2004;24(3):721-735, vii.
8. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50(6):2009-2015.
9. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743-746.
10. Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica. 2004;89(11):ECR42.
11. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950-952.
12. Procop GW, Roberts GD. Emerging fungal diseases: the importance of the host. Clin Lab Med. 2004;24(3):691-719, vi-vii.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
14. Chandrasekar P. Invasive mold infections: recent advances in management approaches. Leuk Lymphoma. 2009;50(5):703-715.
15. Ruhnke M, Bohme A, Buchheidt D, et al. Diagnosis of invasive fungal infections in hematology and oncology - guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol. Epub 2011 Sep 23.
16. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-e93.
17. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501-517.
18. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43(10):1647-1657.
19. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116-4123.
20. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3): 361-392.
21. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49(Suppl 1):31-36.
22. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991;10(8): 665-668.
23. Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis. 2003;36(2):e14-e18.
24. Krcmery V, Barnes AJ. Non-albicans Candida spp causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002;50(4): 243-260.
25. Colombo AL, Melo AS, Crespo Rosas RF, et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis. 2003;46(4): 253-257.
26. Araujo Ribeiro M, Alastruey-Izquierdo A, Gomez-Lopez A, Rodriguez- Tudela JL, Cuenca-Estrella M. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol. 2008;25(4):221-225.
27. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42(10):4419-4431.
28. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol. 2003;41(12): 5525-5529.
29. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 1998;26(5):1092-1097.
30. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999;37(7):2343-2345.
31. Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol. 1999;37(5):1606-1609.
32. Iwen PC, Rupp ME, Bishop MR, et al. Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. J Clin Microbiol. 1998;36(12):3713-3717.
33. Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis. 2006;12(3): 403-408.
34. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov, a new sibling species of A. fumigatus. Eukaryot Cell. 2005;4(3):625-632.
35. Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother. 2004;48(4):1197-1203.
36. Pujol I, Guarro J, Gené J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp strains. J Antimicrob Chemother. 1997;39(2):163-167.
37. Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390): 1142-1151.
38. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61-e65.
39. Cuenca-Estrella M, Ruiz-Díez B, Martinez-Suárez JV, Monzón A, Rodríguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother. 1999;43(1):149-151.
40. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother. 1995;39(6):1361-1364.
41. Perdomo H, Sutton DA, Garcia D, et al. Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol. 2011;49(1): 243-256.
42. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308-329.
43. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27(2):296-302.
44. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis. 2003;37(3):415-425.
45. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31(5):1155-1163.
46. Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236-244.
47. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10):764-771.
48. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(140):1391-1402.
49. Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29(5):415-420.
50. Ellis M, Frampton C, Joseph J, et al. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol. 2006;55(Pt 10): 1357-1365.
51. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4): 225-234.
52. USA FDA Regulations. http://www.fda.gov/drugs/default.htm.
53. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11-41.
54. Kubiak DW, Bryar JM, McDonnell AM, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32(4):637-648.
55. Waknine Y. FDA approvals. Avelox, Avandaryl, Trileptal. Available at: http://www.medscape.com/viewarticle/518278?rss. Accessed Februar 11, 2006 [cited 2011 Oct 24].